Several common biological properties between cancer cells and embryonic stem (ES) cells suggest the possibility that some genes expressed in ES cells might have important roles in cancer cell growth. The transcription factor ZFP57 is expressed in self-renewing ES cells and its expression level decreases during ES cell differentiation. This study showed that ZFP57 is involved in the anchorageindependent growth of human fibrosarcoma HT1080 cells in soft agar. ZFP57 overexpression enhanced, whereas knockdown suppressed, HT1080 tumor formation in nude mice. Furthermore, ZFP57 regulates the expression of insulin-like growth factor 2 (IGF2), which has a critical role in ZFP57-induced anchorage-independent growth. ZFP57 also promotes anchorage-independent growth in ES cells and immortal fibroblasts. Finally, immunohistochemical analysis revealed that ZFP57 is overexpressed in human cancer clinical specimens. Taken together, these results suggest that the ES-specific transcription factor ZFP57 is a novel oncogene.
INTRODUCTION
Embryonic stem (ES) cells are derived from pluripotent cells of the early mammalian embryo and are capable of unlimited, undifferentiated proliferation in vitro.
1,2 Leukemia inhibitory factor can maintain the self-renewal and pluripotency of mouse ES cells. 3 Similarly, several transcription factors have important roles in the self-renewal of ES cells. 4 For example, the POU-family transcription factor Oct3/4 is an essential player in self-renewal and often acts together with the SRY-related HMG-box protein Sox2 to regulate the expression of transcription factors important to self-renewal. [5] [6] [7] Nanog is a homeobox transcription factor whose overexpression can bypass the requirement for leukemia inhibitory factor in selfrenewal, although it is dispensable for self-renewal. [8] [9] [10] Extensive studies have revealed that these transcription factors form networks and stimulate the expression of a set of genes that maintain self-renewal in ES cells. 11, 12 Interestingly, ES cells share many biological properties with cancer cells. For example, when injected into nude mice, ES and cancer cells can produce benign and malignant tumors, respectively. Both cell types have a rapid cell cycle. Telomerase activity is very high in both cells, which allows them to proliferate indefinitely. In addition, several signal transduction pathways seem to be commonly used in both ES cell self-renewal and cancer cell growth. 13, 14 For example, the STAT3 pathway, which has a central role in ES cell self-renewal, 15, 16 is activated in several types of cancer cells. 17 The Wnt/b-catenin pathway, whose activation is associated with tumorigenesis in many tissues, 18 is involved in ES cell self-renewal. [19] [20] [21] Gli, a central signaling molecule in the Hedgehog pathway that is activated in a broad spectrum of human tumors, 22 promotes the maintenance of ES cells. 23 These similarities have raised the possibility that some molecules involved in ES cell self-renewal may have important roles in cancer cell growth and encouraged us to search for an oncogene in self-renewing ES cells.
Here, we report the involvement of the ES-specific transcription factor ZFP57 in cancer cell growth. We demonstrate that ZFP57 is involved in the anchorage-independent growth of human fibrosarcoma HT1080 cells both in vitro and in vivo and that it acts by regulating the expression of insulin-like growth factor 2 (IGF2). In addition, we show that this transcription factor is also involved in the growth of mouse ES cells in soft agar and can stimulate the anchorage-independent growth of mouse NIH3T3 cells. Furthermore, we observed the overexpression of ZFP57 in tumor tissues from cancer patients, suggesting that ZFP57 is a novel oncogene.
RESULTS
Search for stem cell genes that promote anchorage-independent growth in HT1080 cells To identify stem cell genes involved in tumor growth, we cloned several genes from self-renewing mouse ES cells and examined the effect of their ectopic expression on anchorage-independent growth, a property of cancer cells important for tumor formation (Supplementary Figure S1) . As a result, we found that Lrh1 (also known as Nr5a2), Nanog and Zfp57 can promote anchorageindependent growth in human fibrosarcoma HT1080 cells. The involvement of LRH1 and NANOG in tumor growth has already been reported. 24, 25 In this study, therefore, we focused our attention on ZFP57.
Involvement of ZFP57 in the anchorage-independent growth of HT1080 cells As we used mouse Zfp57 for screening, we first confirmed that human ZFP57 also promotes anchorage-independent growth. As shown in Figures 1a-c , overexpression of human ZFP57 enhanced the growth of HT1080 cells in soft agar. We next examined the requirement of ZFP57 for anchorage-independent growth in HT1080 cells by knockdown experiments using artificial micro RNA (miRNA) against ZFP57. To avoid any off-target effect, we used two independent ZFP57 miRNA constructs, ZFP57 miRNA(349) and ZFP57 miRNA(427). Quantitative RT-PCR confirmed that both ZFP57 miRNAs suppress the expression of endogenous ZFP57 mRNA (Figure 3b ). Using these miRNAs, we found that ZFP57 knockdown suppresses the growth of HT1080 in soft agar (Figure 1d ). We confirmed that the suppression of soft agar growth by ZFP57 miRNA can be restored by overexpression of Zfp57 (Supplementary Figure S2) . These results suggest that ZFP57 is involved in the anchorage-independent growth of HT1080 cells.
ZFP57 is involved in tumor formation in nude mice
To determine whether ZFP57 is required for anchorage-independent growth in HT1080 cells in vivo, we established a HT1080 transfectant in which ZFP57 can be knocked down by the addition of 4-hydroxytamoxifen (4-HT) (Supplementary Figure S3) . We confirmed that 4-HT treatment reduces the expression of ZFP57 and suppresses growth in soft agar. After pretreatment with 4-HT, we implanted the transfectant cells into nude mice subcutaneously and measured the size of HT1080-derived tumors. We observed that the depletion of ZFP57 suppresses tumor growth in nude mice (Figure 2a ). We next examined the effect of ZFP57 overexpression on HT1080 tumor formation. As in the case of in vitro experiments, we observed that the overexpression of ZFP57 promotes tumor growth in vivo (Figure 2b ). Overexpression of ZFP57 in the resulting tumors was confirmed by quantitative RT-PCR (Supplementary Figure S4) . These results indicate that ZFP57 is involved in anchorage-independent growth in HT1080 cells both in vitro and in vivo.
IGF2 is a downstream gene of ZFP57 To elucidate the molecular mechanism behind ZFP57-mediated anchorage-independent growth, we searched for a target gene of ZFP57. In embryo and ES cells, Zfp57 regulates the expression of a variety of imprinted genes. 26, 27 Among imprinted genes, IGF2 is involved in tumorigenesis in various cancers. 28, 29 We therefore explored the possibility that IGF2 may be a downstream gene of ZFP57 in HT1080 cells.
Based on previous reports showing binding of ZFP57 to the imprinting control region (ICR) of IGF2-H19 in ES cells, 27 we first examined whether the same was true in HT1080 cells. ChIP analysis revealed that ZFP57 binds to the region containing the ZFP57-binding motif within the IGF2-H19 ICR in HT1080 cells (Figure 3a) . Furthermore, we found that IGF2 expression is suppressed upon knockdown of ZFP57 (Figure 3b ). We confirmed that the ZFP57 knockdown-mediated suppression of IGF2 expression can be recovered by Zfp57 overexpression (Supplementary Figure S5) . These results suggest that ZFP57 regulates IGF2 expression in HT1080 cells.
IGF2 is required for anchorage-independent growth in HT1080 cells Since we identified IGF2 as a downstream gene of ZFP57, we explored the possibility that IGF2 may be required for the ZFP57-mediated anchorage-independent growth of HT1080 cells.
First, we assessed the existence of functional IGF2 signaling in HT1080 cells. To induce cell proliferation and survival, IGF2 must bind to the IGF1 receptor and thereby activate AKT. 28, 29 Western blot analysis revealed that the IGF1 receptor is expressed in HT1080 cells (Figure 4a ). When we stimulated HT1080 cells with recombinant human IGF2 in serum-free conditions, we observed AKT phosphorylation at Thr-308 and Ser-473, indicating activation of AKT (Figure 4b ). These observations suggest that the IGF2 signaling pathway is functional in HT1080 cells.
Next, we examined the effect of ZFP57 knockdown on the phosphorylation status of AKT. When we compared the amount of phosphorylated AKT between ZFP57 knockdown HT1080 cells and control HT1080 cells, we found that ZFP57 knockdown reduces AKT phosphorylation (Figure 4c ), suggesting that ZFP57-stimulated IGF2 upregulation leads to AKT activation in HT1080 cells.
To examine the requirement of IGF2 in anchorage-independent growth in HT1080 cells, we inhibited IGF2 activity with an anti-IGF2-neutralizing antibody. As shown in Figure 4d , the neutralizing Figure S6) . Furthermore, the neutralizing antibody suppressed the ZFP57-induced anchorage-independent growth of HT1080 cells (Figure 4e ).
We also examined the requirement of IGF2 in tumor formation by xenograft assay (Figure 4f ). When IGF2 knockdown HT1080 cells were implanted into nude mice, IGF2 knockdown significantly inhibited tumor formation. Moreover, we found that IGF2 knockdown attenuates the enhanced tumor growth by Zfp57 overexpression (Figure 4g and Supplementary Figure S7) .
These results suggest that IGF2 is a key molecule in ZFP57-mediated anchorage-independent growth. Zfp57 is involved in the anchorage-independent growth of ES cells ES cells can grow in anchorage-independent conditions, as expected from the fact that they can give rise to benign tumors called teratomas when injected into immunodeficient mice. 3 Previously, we established Zfp57 knockout ES cells and showed that Zfp57 is dispensable for ES cell self-renewal and proliferation in anchorage-dependent conditions. 30 As we found here that ZFP57 is involved in anchorage-independent growth in HT1080 cells, we examined whether this was true in ES cells. To assess the effect of Zfp57 level on the colony-forming capacity of ES cells in soft agar, we compared 1F9 cells (Zfp57 þ / À ES cells that express Zfp57) to 2E9 cells (Zfp57 À / À ES cells that lost expression of Zfp57). 30 Both cells were seeded into soft agar and allowed to grow. About 1 week later, we observed that the number of viable 2E9 colonies was significantly lower than that of viable 1F9 colonies ( Figure 5 ), suggesting that Zfp57 is involved in anchorage-independent growth in ES cells. We confirmed that the reduction in colony number can be recovered by overexpression of exogeneous Zfp57 (Supplementary Figure S8) . These results further suggest that ZFP57 has an important role in anchorage-independent growth.
ZFP57 transforms NIH3T3 cells
The importance of ZFP57 in anchorage-independent growth encouraged us to explore the possibility that ZFP57 may be an oncogene. The immortal mouse fibroblast cell line NIH3T3 can hardly grow in an anchorage-independent manner and has been used to evaluate the transforming activity of individual genes.
To determine whether ZFP57 has transforming potential, we overexpressed ZFP57 in NIH3T3 cells and performed a soft agar assay. As shown in Figure 6 , colony formation in soft agar by parental NIH3T3 cells was very ineffective. By contrast, ZFP57 overexpression allowed NIH3T3 cells to grow efficiently in soft agar, suggesting that ZFP57 possesses oncogenic properties.
ZFP57 expression in cancer patients
Finally, we investigated the expression of ZFP57 in patients with different kinds of cancers by immunohistochemical staining. When compared with normal tissues, we observed the overexpression of ZFP57 in several cancer tissues ( Figure 7 , Table 1 ). In pancreatic cancer, more than 70% of the patients tested were positive for ZFP57. In gastric, breast, colon and esophageal cancer tissues, about 40% of the patients were ZFP57-positive. By contrast, ZFP57 overexpression was rarely observed in hepatocellular carcinoma and cholangiocellular carcinoma tissues. The specificity of anti-human ZFP57 antibody was confirmed by western blotting (Supplementary Figure S9) . These results suggest that ZFP57 functions as an oncogene in some human cancers.
Moreover, we performed immunohistochemical staining using anti-IGF2 antibody (Supplementary Figure S10) and found a statistically significant correlation between ZFP57 and IGF2 expression in esophageal and breast cancers (P ¼ 0.03169 and 0.00617, respectively, Chi-square test). No significant correlation was observed in other cancers. These results suggest that ZFP57 overexpression leads to IGF2 overexpression in some types of cancers.
DISCUSSION
The transcription factor Zfp57 was originally identified as an undifferentiated cell-specific gene in F9 embryonal carcinoma cells. 31 The mouse ZFP57 protein consists of 421 amino acids and contains one Kruppel-associated box (KRAB) domain and five zinc fingers, whereas the human ZFP57 protein consists of 536 amino acids with one KRAB domain and seven zinc fingers. In ES cells, Zfp57 is downstream of Stat3 and Oct3/4, and therefore shows self-renewal-specific expression. 30 In adult mouse organs, Zfp57 is highly expressed in testis and brain. 31, 32 Loss of the zygotic function of Zfp57 causes partial lethality, whereas eliminating both the maternal and zygotic functions of Zfp57 leads to complete embryonic lethality. 26 Several reports have suggested that this transcription factor binds to KRAB-associated protein 1 (KAP1), a scaffold protein for various heterochromatin-inducing factors, through its KRAB domain, and is involved in genome imprinting by recruiting KAP1 to several ICRs. 26, 27, 33 In addition, mutations in the ZFP57 gene result in transient neonatal diabetes mellitus type 1, possibly through Plagl1 overexpression. 34, 35 The role of ZFP57 in tumorigenesis has not been elucidated yet.
In this study, we demonstrated the involvement of ZFP57 in the anchorage-independent growth of tumor cells both in vitro and in vivo. When cultured in the absence of adhesion to substratum, normal adherent cells undergo apoptosis, a phenomenon known as anoikis. 36, 37 By contrast, transformed cells are able to survive and grow even in the absence of anchorage. Anchorageindependent growth is therefore a major characteristic of transformed cells, and in fact shows a good correlation with tumor malignancy. 38, 39 In addition to cancer cells, Zfp57 is involved in ES cell anchorage-independent growth, suggesting that ZFP57-mediated anchorage-independent growth is not restricted to cancer cells. Furthermore, ZFP57 enables immortal NIH3T3 fibroblasts to proliferate independently of anchorage. These results strongly suggest that ZFP57 plays an important role in anchorage-independent growth.
We demonstrated that, as a molecule downstream of ZFP57, IGF2 has a critical role in anchorage-independent growth in HT1080 cells. To promote cell proliferation, IGF2 binds to the IGF1 receptor and stimulates PI3 kinase activity, leading to the activation of AKT. It is well-known that AKT activation has an important role in anchorage-independent growth in cancer cells. 37 We confirmed the expression of the IGF1 receptor and observed that IGF2 stimulation leads to activation of AKT in HT1080 cells. Furthermore, we found that ZFP57 knockdown reduces AKT phosphorylation. These observations suggest that ZFP57-induced IGF2 stimulates HT1080 cells in an autocrine manner and activates the AKT pathway to avoid anoikis and promote anchorageindependent growth.
Although overexpression of IGF2 is observed in a variety of cancer cells, 40 its molecular mechanism is not fully understood. A well-known mechanism is loss of imprinting. In normal cells, IGF2 expression is regulated by genome imprinting and transcription of IGF2 mRNA occurs only at the paternal allele. In some cancer cells, however, this imprinting system is not functional and IGF2 mRNA is transcribed from both alleles, resulting in increased expression of IGF2. Imprinting of IGF2 is regulated at the IGF2-H19 ICR, and ZFP57 binds to this region in ES cells. 27 In this study, we also observed the binding of ZFP57 to the IGF2-H19 ICR in HT1080 cells. It is possible therefore that ZFP57 regulates IGF2 expression through loss of imprinting in HT1080 cells, although the previous finding that Zfp57 deficiency has no effect on the expression level of Igf2 in mouse embryo cells does not support this possibility. 26 Our preliminary analysis using bisulfite sequencing suggests that DNA methylation level around the ZFP57-binding region of IGF2-H19 ICR is low in HT1080 cells, also diminishing this possibility. Another mechanism of IGF2 overexpression is through activation of the IGF2 promoter. For example, E2F3 activates the IGF2 promoter and overexpression of E2F3 correlates with IGF2 overexpression in prostate and bladder cancers, 41 suggesting that IGF2 expression in cancer cells is modulated not only by imprinting but also by regulation of IGF2 promoter activity. We are now investigating which mechanism of IGF2 upregulation is employed by ZFP57.
As ZFP57 regulates the expression of various imprinted genes and as the aberrant regulation of imprinted genes causes tumorigenesis, 42, 43 it is possible that other imprinted genes, in addition to IGF2, may function downstream of ZFP57 to promote tumorigenesis. Interestingly, we have already found that ZFP57 regulates the expression of Delta-like homolog 1 (DLK1) in HT1080 cells (Tada et al., unpublished data). An imprinted gene, DLK1, is a non-canonical Notch ligand that has an important role in the growth of several tumors including neuroblastoma and hepatoblastoma. 44 It is possible therefore that DLK1 may be another key imprinted gene in ZFP57-stimulated cancer growth. In addition, non-coding RNAs are possible target genes of ZFP57, since multiple non-coding RNAs are located in the imprinted locus and are involved in tumorigenesis. [45] [46] [47] Identification of another ZFP57 target gene would be of great help to understand the molecular mechanism of ZFP57-induced tumor growth in more detail. (779), and puromycin-resistant clones were injected into nude mice subcutaneously. Mice were killed 2 weeks after injection, and tumor volume was measured. (g) IGF2 knockdown attenuates the enhanced tumor growth due to Zfp57 overexpression. HT1080 cells expressing IGF2 miRNA were transfected with pCAGIH3-mZfp57, and hygromycin-resistant clones were injected subcutaneously. Mice were killed 9 days after injection to measure tumor volume. In both experiments, median values are represented by horizontal bars. *Po0.05 by Mann-Whitney test.
In conclusion, we demonstrated here that the ES-specific transcription factor ZFP57 promotes anchorage-independent growth in HT1080 cells by upregulating IGF2 expression. In addition, ZFP57 enables normal mouse fibroblasts to grow even in the absence of anchorage. Furthermore, we observed the overexpression of ZFP57 in multiple types of cancers. Our data suggest that ZFP57 can function as an oncogene. Our present findings raise several intriguing possibilities. First, as ZFP57 is overexpressed in several tumors, together with the previous findings that ZFP57 is involved in imprinting, it is possible that aberrant regulation of ZFP57 may cause loss of imprinting in some types of cancers. Second, considering that ZFP57 is a stem cell-specific transcription factor involved in tumor growth, it is possible that ZFP57 may be expressed in cancer stem cells and have a role in their growth. Third, as induced pluripotent stem (iPS) cells have a similar gene expression profile to ES cells, 48 it is likely that ZFP57 is expressed in iPS cells. Considering that ZFP57 has transforming ability, it is possible that the high expression of ZFP57 in iPS cells may increase the risk of tumor formation during cell therapy using iPS-derived cells. These possibilities will be explored in a future study.
MATERIALS AND METHODS

Cell lines and antibodies
HT1080 fibrosarcoma cells and HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum. NIH3T3 cells were cultured in DMEM containing 10% fetal calf serum. ES cells were cultured on gelatin-coated dishes with leukemia inhibitory factor-supplemented DMEM as described previously, 49 except that the culture medium contained 150 mM 1-thioglycerol (Wako Pure Chemical Industries, Osaka, Japan) instead of 40 mM b-mercaptoethanol. All cell lines were maintained in a humidified atmosphere of 5% CO 2 .
Anti-IGF2-neutralizing antibody (clone S1F2) was purchased from Millipore (Billerica, MA, USA). Control IgG (ab37355) was from Abcam (Cambridge, MA, USA). Anti-myc antibody (clone 9E10) and anti-a-tubulin antibody (clone 2F9) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and MBL (Nagoya, Japan), respectively. Antibodies against AKT (no. 4691), phospho-AKT (Thr308) (no. 2965), phospho-AKT (Ser473) (no. 4060) and the IGF1 receptor (no. 9750) were from Cell Signaling Technology (Boston, MA, USA).
Plasmid construction
The coding sequences of human and mouse ZFP57 (NCBI accession numbers: NM_001109809 and NM_009559, respectively) were amplified from cDNA synthesized from HT1080 cell total RNA and A3-1 ES cell total RNA, respectively, using primers listed in Supplementary Table S1 . pCAGIPmyc-hZFP57, pCAGIP-HA-hZFP57 and pCAGIP-Flag-hZFP57 were constructed by inserting a myc-, HA-or flag-tagged human ZFP57-coding fragment into the mammalian expression vector pCAG-IP. 49 Plasmid pCAG- Table S1 ). EmGFP-control miRNA, EmGFP-ZFP57 miRNA(349 or 427) and EmGFP-IGF2 miRNA(779) were transferred from pGW/EmGFP constructs to pEBM-CAGIP to obtain pEBM-CAGIP-EmGFP-control, pEBM-CAGIP-EmGFP-ZFP57(349 or 427) and pEBM-CAGIP-EmGFP-IGF2(779), respectively. The plasmid pCAG-IG1a was constructed by replacing the IRES-puromycin resistance gene of pCAG-IP with IRES-hrGFP1a in pIRES-hrGF1a (Stratagene, La Jolla, CA, USA). An inducible expression vector, pCALiPL-IG1a, was constructed by inserting a loxP-IRES-puromycin resistance-loxP cassette into pCAG-IG1a. EmGFP-ZFP57 miRNA(427) was transferred from pGW/EmGFP-ZFP57(427) into pCALiPL-IG1a to produce pCALiPL-IG1a-EmGFP-hZFP57(427).
Establishment of stable cell lines
To establish ZFP57-overexpressing HT1080 cells, HT1080 cells were transfected with pCAGIP-myc-hZFP57 using Lipofectamine 2000 (Invitrogen) and selected with 0.3 mg/ml puromycin for 2 weeks. Resistant clones were pooled and subjected to experiments. Similarly, HT1080 cells were transfected with pEBM-CAGIP-EmGFP constructs to obtain HT1080 cells with ZFP57 knockdown.
To establish the cell line with inducible ZFP57 knockdown HT1080/ pCALiPL-ZFP57(427), HT1080 cells were transfected with both pCALiPLIG1a-EmGFP-hZFP57(427) and pCAG-myc-ER-Cre-ER, and selected with puromycin. Each resistant clone was assessed for 4-HT-dependent knockdown of ZFP57. Quantitative RT-PCR Total RNA was extracted from individual cultured cells using Sepasol RNA I super G (Nacalai Tesque), and cDNA synthesis was performed with ReverTra Ace (Toyobo, Osaka, Japan). Real-time PCR analysis using SYBR green was conducted using the Mx3000p System (Stratagene), and results were normalized to b-actin expression. Primers are listed in Supplementary  Table S1 .
Western blot analysis
Cells were lysed in cell lysis buffer (20 mM Hepes-NaOH (pH 7.2), 10 mM MgCl 2 , 1 mM EDTA, 10 mM sodium fluoride, 25 mM b-glycerophosphate, 1 mM sodium orthovanadate, 20 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mg/ml pepstatin A, 1% Nonidet P-40 and 10% glycerol). Lysates were then mixed with 1 Â sample buffer (6% glycerol, 10 mM Tris-HCl (pH 6.8), 2% SDS, 50 mM DTT, 2 mM EDTA, and 0.002% Coomassie Brilliant Blue R250) and heat-denatured. Samples were subjected to SDS-polyacrylamide gel electrophoresis and electrophoretically transferred to nitrocellulose membranes. The membranes were then probed with antibodies, and signals were visualized using enhanced chemiluminescence reagents (Perkin-Elmer, Norwalk, CT, USA) with the LAS-1000 image analyzer (Fuji Film, Tokyo, Japan). In all experiments, a-tubulin was used as an internal control.
Soft agar assay and xenograft experiments
For soft agar assays, cells were seeded in 2.4 ml of culture medium containing 0.5% Sea Plaque agarose (Lonza, Rockland, ME, USA), overlaid on 3 ml of 0.53% agarose in 6-cm dishes. The cultures were maintained for about 2 weeks. Viable colonies were stained with 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Nacalai Tesque). Dishes were then scanned with an ES-2200 scanner (Epson, Nagano, Japan), and the number of stained colonies was counted by Image-J (NIH, Bethesda, MD, USA). The tumorigenic potential of HT1080/pCALiPL-ZFP57 cells was assessed in 10 CAnN,Cg-Foxn1 Chromatin immunoprecipitation (ChIP) assay HT1080 cells were transfected with pCAGIP-Flag-hZFP57 and cultured for 2 days. After harvest, cells were processed for ChIP assay using the OneDay ChIP kit (Nippon Gene, Tokyo, Japan). Briefly, cells were fixed with 1% formaldehyde for 10 min at room temperature and the chromatin was sheared to an average fragment size of 500-1000 bp by sonication with a Bioruptor (Cosmo Bio, Tokyo, Japan). After cross-linking was quenched with glycine, whole cell extracts were prepared for chromatin immunoprecipitation. Fragmented chromatin was used in each reaction. DNA was immunoprecipitated with 5 mg of anti-flag antibody (M2; Sigma, St Louis, MO, USA) or normal mouse IgG (sc-2025; Santa Cruz Biotechnology). DNA from the immunoprecipitates or from 1% of the input material was analyzed by PCR using primers specific for the IGF2-H19 ICR (Supplementary Table S1 ).
Immunohistochemical analysis
The expressions of ZFP57 and IGF2 in carcinomas were examined immunohistochemically using the EnVision þ System (DAKO, Copenhagen, Denmark). Tumor specimens were fixed in 10% formalin and embedded in paraffin. Dewaxed 4-mm sections were incubated with protein-blocking serum for 10 min to block non-specific binding. The sections were then incubated with rabbit anti-human ZFP57 polyclonal antibody (U-18; Santa Cruz Biotechnology) (1:50) or rabbit anti-human IGF2 polyclonal antibody (LS-B7415; LifeSpan Biosciences, Seattle, WA, USA) (5 mg/ml) at 4 1C overnight. After washing, EnVision þ polymer solution was applied for 1 h. The reaction products were visualized with diaminobenzidine. The specimens were then lightly counterstained with hematoxylin. Written consent was obtained from all patients, and the project was approved by the Ethics Committee for Human Genome/Gene Analysis Research at Kanazawa University Graduate School of Medical Sciences.
